DYN

Dyne Therapeutics, Inc. Common Stock

18.07

USD

+0.71

+4.09%

Nov 06, 15:59 UTC -5

Closed

After-Market

18.05

-0.02

-0.13%

Dyne Therapeutics, Inc. Common Stock (DYN) Earnings

DYN Earnings Reports

Positive Surprise Ratio

DYN beat 9 of 24 last estimates.

38%

Next Report

Date of Next Report

Mar 01, 2027

Estimate for Q4 26 (Revenue/ EPS)

-$0.93

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

+22.37%

Dyne Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 02, 2026, DYN reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.92 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.93 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Guardian Pharmacy Services, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.30

Actual

$0.33

Surprise

+7.84%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Xeris Biopharma Holdings, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.02

Actual

$0.06

Surprise

+144.90%

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Collegium Pharmaceutical, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.89

Actual

$1.96

Surprise

+3.17%

Ironwood Pharmaceuticals, Inc. - Class A

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.32

Actual

$0.36

Surprise

+9.16%

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.32

Actual

-$0.36

Surprise

-11.15%

Profound Medical Corp. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.18

Actual

-$0.21

Surprise

-11.41%

Akebia Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.03

Actual

-$0.04

Surprise

-6.95%

FAQ

What were Dyne Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Dyne Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Dyne Therapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Dyne Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 01, 2027.

What are the forecasts for Dyne Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Dyne Therapeutics, Inc. Common Stock is expected to report EPS of -$0.93 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.